Unigene is building a robust portfolio of proprietary partnerships in this expanding drug class based on the Company s Peptelligence platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high yield, scalable and reproducible E. coli based manufacturing technologies.
Quote | Unigene Labs Inc Com (OTCMKTS:UGNEQ)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.0003 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 07/02/2019 09:39:55 am |
News | Unigene Labs Inc Com (OTCMKTS:UGNEQ)
Message Board Posts | Unigene Labs Inc Com (OTCMKTS:UGNEQ)
Subject | By | Source | When |
---|---|---|---|
UGNEQ registration revoked: | Renee | investorshub | 07/01/2019 1:55:07 PM |
UGNEQ SEC Suspension for severely delinquent Financials/Filings: | Renee | investorshub | 09/14/2018 1:34:08 PM |
Anyone have thoughts on the out of the | FarmerMatt | investorshub | 03/20/2018 8:35:12 PM |
BOOM! | rising | investorshub | 10/24/2017 11:43:41 PM |
$UGNEQ, trending up again here the past couple days. | Garyst | investorshub | 12/30/2016 3:23:50 AM |